|
|
(HealthNewsDigest.com) – “Survival from advanced pancreatic cancer is poor, in part due to dense fibrosis of the tumor microenvironment, increased number of [tumor-promoting] polarized macrophages that promote angiogenesis and invasion and lack of ‘target-specific’ therapy. Herein, we report that a tumor vaccine that selectively targets gastrin, decreases pancreatic cancer growth and metastases. Furthermore, the gastrin vaccine, [polyclonal antibody stimulator], alters the tumor microenvironment rendering it more responsive to immunotherapy with a PD-1 immune checkpoint antibody.”
This study is highlighted as one of October’s “best of the best” as part of the American Physiological Society’s APSselect program.